Impact of surgical stress on advanced ovarian cancer progression and survival in relation with timing of chemotherapy: bedside to bench
Investigating the impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer: a multi-institutional study of 711 patients
Impact of wound healing on ovarian cancer progression and sensitivity to platinum-based agents: a pilot study using a syngeneic orthotopic mouse model
Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies with 5 year overall survival rates of about 30% in advanced disease.
Standard treatment consists of maximal cytoreductive surgery and adjuvant chemotherapy. However, there is no consensus for the optimal interval between surgery and initiation of chemotherapy and delays of 6-8 weeks are allowed in most clinical trials.
The objective of this study is to investigate the impact of the interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy on overall survival for advanced EOC (FIGO stage III and IV).